azn201212036k1.htm
 
 
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
Report of Foreign Issuer
 
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of December 2012

 
Commission File Number: 001-11960

 
AstraZeneca PLC
 
 
2 Kingdom Street, London W2 6BD
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F X      Form 40-F __
 
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______           
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
 
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
 
Yes __     No X
 
 
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
 

 
 

 
 
 
BLOCK LISTING SIX MONTHLY RETURN
 
Information provided on this form must be typed or printed electronically and provided to anris.
 
Date: 3 DECEMBER 2012
 
  Name of applicant :
 
  ASTRAZENECA PLC
   Name of scheme:
  ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA SAVINGS-RELATED SHARE OPTION PLAN;   
   ASTRAZENECA ALL-EMPLOYEE SHARE PLAN
   Period of return:
 
From:
  1 JUNE 2012
  To:
 30 NOVEMBER 2012
   Balance of unallotted securities under scheme(s) from previous return:
 
  7,757,874
  Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any  
  increase has been applied for):
 
  0
  Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):
 
  4,790,794
  Equals: Balance under scheme(s) not yet issued/allotted at end of period:
 
  2,967,080
         
 
  Name of contact:
   MARTIN BENNETT
  Telephone number of contact:
   020 7604 8157
 
 

 
 
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
AstraZeneca PLC
 
Date: 03 December 2012
By: /s/ Adrian Kemp
 
Name: Adrian Kemp
 
Title: Company Secretary